PetVivo Holdings, Inc. Airs on Fox Business Network

MINNEAPOLIS, Jan. 04, 2018 -- (OTCMARKETS:PETV) PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company, is happy to announce that the interview recently aired on the FOX Business Network, Saturday, December  23, 2017, at 3:00 PM Eastern/12:00 AM Pacific, on “New to the Street” is now available for viewing on demand on our company website www.petvivo.com and on the ”New to the Street" YouTube channel  for those that may have missed the broadcast.

John Lai, President of Petvivo Holdings Inc. stated, “… that with the forthcoming launch of the Kush product and the impact that we are hoping for, it will bring a new quality of life to those dogs and horses we love. We are expecting a warm welcome with our product to the delivery of healthcare to the veterinary world. We felt it was important to bring it to the public at large and that television would be one of the best mediums to get the message out there. Therefore, we are proud to make available the interview on our website and through the New to the Street" YouTube channel.

FMW Media Works Corp. ("New To The Street") is a leading provider of business profiles and special corporate programming. FMW Media Works produces "New to the Street" which paves the way to the latest financial issues, offering a blend of business and financial services news reporting and in-depth interviews relating to new products, economic analysis, and public company profiles. "New to the Street" airs as paid TV programming and airs in the United States reaching potentially 100 million homes, in Canada reaching potentially more than 5.3 million homes and viewed on other select International stations. Visit www.NewToTheStreet.com.

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK:PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo's strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com )   

Forward-Looking commercial Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

CONTACT:

Wes Hayne
CEO
PetVivo Holdings, Inc.
Email: [email protected]
Main: 952-405-6216
Direct: (763) 443-7272